High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease: An initial foray

Olaf Schulz, Markus Reinicke, Gunnar H. Berghoefer, Ricarda Bensch, Jochen Kraemer, Ingolf Schimke, Allan S Jaffe

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: How to use the information from novel high sensitivity troponin assays in stable cardiac patients is unclear. Preliminary data from randomized controlled trial analyses suggest it helps with risk stratification. We investigated the determinants, diagnostic impact and prognostic value of a novel high-sensitive cardiac troponin I (hs-cTnI) assay in patients with stable cardiac disease. Methods: hs-cTnI was measured with a pre-commercial assay in 222 outpatients after clinical testing before cardiac catheterization. Mean follow-up was 1103. ±. 299 days. Results: hs-cTnI was detectable in all patients (median (interquartile range) 6.20 (4.85;8.25) ng/l). Creatinine (p<. 0.001), systolic wall stress (p= 0.004), the presence of myocardial impairment (p= 0.049) and coronary artery stenosis ≥70% (p= 0.050) were predictors of hs-cTnI concentration.hs-cTnI values could not distinguish elevations due to myocardial abnormalities from those related to coronary artery abnormalities. Patients with elevations above the 99th percentile had a higher rate of hospitalizations but otherwise prognosis was not predicted robustly by hs-cTnI values. Conclusion: Stable cardiovascular patients have detectable hs-cTnI concentrations irrespective of their underlying disease. In this heterogeneous group of patients with diverse etiologies for cardiac disease, values were not helpful in distinguishing the etiology of the elevations or in predicting prognosis.

Original languageEnglish (US)
Pages (from-to)812-817
Number of pages6
JournalClinica Chimica Acta
Volume411
Issue number11-12
DOIs
StatePublished - Jun 2010

Fingerprint

Troponin I
Cardiovascular Diseases
Assays
Heart Diseases
Troponin
Coronary Stenosis
Cardiac Catheterization
Creatinine
Coronary Vessels
Hospitalization
Outpatients
Randomized Controlled Trials
Testing

Keywords

  • Chronic cardiac disease
  • High sensitivity troponin

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Cite this

High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease : An initial foray. / Schulz, Olaf; Reinicke, Markus; Berghoefer, Gunnar H.; Bensch, Ricarda; Kraemer, Jochen; Schimke, Ingolf; Jaffe, Allan S.

In: Clinica Chimica Acta, Vol. 411, No. 11-12, 06.2010, p. 812-817.

Research output: Contribution to journalArticle

Schulz, Olaf ; Reinicke, Markus ; Berghoefer, Gunnar H. ; Bensch, Ricarda ; Kraemer, Jochen ; Schimke, Ingolf ; Jaffe, Allan S. / High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease : An initial foray. In: Clinica Chimica Acta. 2010 ; Vol. 411, No. 11-12. pp. 812-817.
@article{7701f29f1ff54f9eacdc66f0e1296686,
title = "High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease: An initial foray",
abstract = "Background: How to use the information from novel high sensitivity troponin assays in stable cardiac patients is unclear. Preliminary data from randomized controlled trial analyses suggest it helps with risk stratification. We investigated the determinants, diagnostic impact and prognostic value of a novel high-sensitive cardiac troponin I (hs-cTnI) assay in patients with stable cardiac disease. Methods: hs-cTnI was measured with a pre-commercial assay in 222 outpatients after clinical testing before cardiac catheterization. Mean follow-up was 1103. ±. 299 days. Results: hs-cTnI was detectable in all patients (median (interquartile range) 6.20 (4.85;8.25) ng/l). Creatinine (p<. 0.001), systolic wall stress (p= 0.004), the presence of myocardial impairment (p= 0.049) and coronary artery stenosis ≥70{\%} (p= 0.050) were predictors of hs-cTnI concentration.hs-cTnI values could not distinguish elevations due to myocardial abnormalities from those related to coronary artery abnormalities. Patients with elevations above the 99th percentile had a higher rate of hospitalizations but otherwise prognosis was not predicted robustly by hs-cTnI values. Conclusion: Stable cardiovascular patients have detectable hs-cTnI concentrations irrespective of their underlying disease. In this heterogeneous group of patients with diverse etiologies for cardiac disease, values were not helpful in distinguishing the etiology of the elevations or in predicting prognosis.",
keywords = "Chronic cardiac disease, High sensitivity troponin",
author = "Olaf Schulz and Markus Reinicke and Berghoefer, {Gunnar H.} and Ricarda Bensch and Jochen Kraemer and Ingolf Schimke and Jaffe, {Allan S}",
year = "2010",
month = "6",
doi = "10.1016/j.cca.2010.02.066",
language = "English (US)",
volume = "411",
pages = "812--817",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "11-12",

}

TY - JOUR

T1 - High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease

T2 - An initial foray

AU - Schulz, Olaf

AU - Reinicke, Markus

AU - Berghoefer, Gunnar H.

AU - Bensch, Ricarda

AU - Kraemer, Jochen

AU - Schimke, Ingolf

AU - Jaffe, Allan S

PY - 2010/6

Y1 - 2010/6

N2 - Background: How to use the information from novel high sensitivity troponin assays in stable cardiac patients is unclear. Preliminary data from randomized controlled trial analyses suggest it helps with risk stratification. We investigated the determinants, diagnostic impact and prognostic value of a novel high-sensitive cardiac troponin I (hs-cTnI) assay in patients with stable cardiac disease. Methods: hs-cTnI was measured with a pre-commercial assay in 222 outpatients after clinical testing before cardiac catheterization. Mean follow-up was 1103. ±. 299 days. Results: hs-cTnI was detectable in all patients (median (interquartile range) 6.20 (4.85;8.25) ng/l). Creatinine (p<. 0.001), systolic wall stress (p= 0.004), the presence of myocardial impairment (p= 0.049) and coronary artery stenosis ≥70% (p= 0.050) were predictors of hs-cTnI concentration.hs-cTnI values could not distinguish elevations due to myocardial abnormalities from those related to coronary artery abnormalities. Patients with elevations above the 99th percentile had a higher rate of hospitalizations but otherwise prognosis was not predicted robustly by hs-cTnI values. Conclusion: Stable cardiovascular patients have detectable hs-cTnI concentrations irrespective of their underlying disease. In this heterogeneous group of patients with diverse etiologies for cardiac disease, values were not helpful in distinguishing the etiology of the elevations or in predicting prognosis.

AB - Background: How to use the information from novel high sensitivity troponin assays in stable cardiac patients is unclear. Preliminary data from randomized controlled trial analyses suggest it helps with risk stratification. We investigated the determinants, diagnostic impact and prognostic value of a novel high-sensitive cardiac troponin I (hs-cTnI) assay in patients with stable cardiac disease. Methods: hs-cTnI was measured with a pre-commercial assay in 222 outpatients after clinical testing before cardiac catheterization. Mean follow-up was 1103. ±. 299 days. Results: hs-cTnI was detectable in all patients (median (interquartile range) 6.20 (4.85;8.25) ng/l). Creatinine (p<. 0.001), systolic wall stress (p= 0.004), the presence of myocardial impairment (p= 0.049) and coronary artery stenosis ≥70% (p= 0.050) were predictors of hs-cTnI concentration.hs-cTnI values could not distinguish elevations due to myocardial abnormalities from those related to coronary artery abnormalities. Patients with elevations above the 99th percentile had a higher rate of hospitalizations but otherwise prognosis was not predicted robustly by hs-cTnI values. Conclusion: Stable cardiovascular patients have detectable hs-cTnI concentrations irrespective of their underlying disease. In this heterogeneous group of patients with diverse etiologies for cardiac disease, values were not helpful in distinguishing the etiology of the elevations or in predicting prognosis.

KW - Chronic cardiac disease

KW - High sensitivity troponin

UR - http://www.scopus.com/inward/record.url?scp=77956460987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956460987&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2010.02.066

DO - 10.1016/j.cca.2010.02.066

M3 - Article

C2 - 20188720

AN - SCOPUS:77956460987

VL - 411

SP - 812

EP - 817

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 11-12

ER -